Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763790 | 0.98 | LMNA (0.43) | MEN1KMT2ALMNATDP1THRB | |
| SCHEMBL2670043 | 0.96 | LMNA (0.44) | MEN1KMT2ALMNATDP1THRB | |
| SCHEMBL2915529 | 0.91 | LMNA (0.46) | MEN1KMT2ALMNATDP1THRB | |
| SCHEMBL20495594 | 0.80 | MAOA (0.44) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL30548748 | 0.80 | MAOA (0.44) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL30958574 | 0.75 | ALDH1A1 (0.47) | LMNAALDH1A1MAPTHPGDPKM | |
| SCHEMBL202984 | 0.75 | BCL2 (0.41) | LMNAALDH1A1MAPTHPGDPKM | |
| Cyclopentanamine SCHEMBL28944901 | 0.74 | KMT2A (0.40) | MEN1KMT2ALMNATDP1THRB | |
| SCHEMBL18069256 | 0.74 | MEN1 (0.42) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL6926453 | 0.72 | ERN1 (0.48) | MEN1KMT2ALMNATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103261133-B | Hydrogenation of esters or carbonyl groups with tetradentate amino/imino-hioether based ruthenium complexes | FIRMENICH & CIE | 2015-04-15 | — | — | CN | disclosed |
| EP-2526945-A1 | New CRTH2 Antagonists | Almirall, S.A. (ES) | 2012-11-28 | — | — | EP | disclosed |
| EP-2526945-A1 | New CRTH2 Antagonists | Almirall, S.A. (ES) | 2012-11-28 | — | — | EP | disclosed |
| US-8168673-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2012-05-01 | — | — | US | disclosed |
| EP-2240444-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009093029-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2009-07-30 | — | — | WO | disclosed |
| US-20090192195-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20040242915-A1 | Modified alumina catalyst | BIOCON LIMITED (IN) | 2004-12-02 | — | — | US | disclosed |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | disclosed |
| WO-2004060859-A2 | NOVEL AMIDES THAT ACTIVATE SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
| EP-1427526-A1 | MODIFIED ALUMINA CATALYST | Biocon Limited (IN) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003024591-A1 | MODIFIED ALUMINA CATALYST | BIOCON LIMITED (IN) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192195-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, NR3C2, NR2C2 | MEN1 4578/4885KMT2A 3044/4885LMNA 4029/4885 |
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | MEN1 1311/4885KMT2A 3702/4885LMNA 2027/4885 |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | MEN1 1311/4885KMT2A 3702/4885LMNA 2027/4885 |
| US-20040242915-A1 | Modified alumina catalyst | ADH1A, APEX1, AAAS | MEN1 1728/4885KMT2A 268/4885LMNA 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.